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inTRODUCTiOn
Receptor/ligand interactions of the tumor necrosis factor (TNF) superfamily are associated with 
versatile apoptotic and regulatory signaling pathways in parenchymal tissues and the immunohe-
matopoietic system. Apoptotic signaling mediated by Fas and TNF receptor-1 (TNF-R1) is one of the 
major cytotoxic mechanisms used by immune cells to kill endogenous cells and exogenous pathogens. 
In this capacity, these ubiquitous effector mechanisms of cell death, along with perforin/granzyme, 
are direct mediators of β-cell injury that is inflicted in autoimmune insulitis in type 1 diabetes (T1D). 
At the same time, the TNF family receptor/ligand interactions are prime constituents of immune 
homeostasis that enforce negative regulation of sensitized immunocytes (1–3). All immune cells 
upregulate TNF family receptors upon activation and are therefore submitted to negative regulation 
by apoptosis within the process of activation-induced cell death (AICD), which is also essential to 
termination of inflammation (4).
Tumor necrosis factor family receptor/ligand interactions participate as universal cytotoxic 
mechanisms in physiological turnover of cells, removal of dysfunctional cellular elements, and 
clearance of debris following injury of parenchymal tissues. As ubiquitous injury factors, the TNF 
family ligands concomitantly activate precursors and synergize with other growth factors to induce 
generation of renewed functional parenchymal cells to replace the injured tissue. For example, the 
Fas receptor and the cognate Fas-ligand (FasL) are constitutively expressed and transduce trophic 
regulatory signals in tissues such as glia, neurons, hepatocytes, and endothelium (5–7). Likewise, 
trophic signals are transduced by TNF superfamily receptors in hematopoietic stem and progenitor 
cells, which synergize with other growth factors to foster hematopoiesis under stress conditions 
(8). Therefore, common injury factors such as TNFα and interferons (IFN) couple hematopoietic 
activity to inflammation and injury in order to fuel immune reactions and support initial resolution 
of injury (9).
The Fas/FasL interaction is a common effector mechanism of β-cell apoptosis and islet injury 
under inflammatory conditions, and physiological modulation of immune homeostasis, including 
control of aberrant autoimmune reactions. In the absence of specific characteristics of the toxic and 
anti-inflammatory pathways, it is questioned whether neutralization or reinforcement of the Fas/
FasL interaction is of therapeutic value in autoimmune disorders. We examine a wide array of evi-
dence arguing in favor of and against therapeutic neutralization of Fas and/or FasL and conversely, 
consider the feasibility of implementation of this molecular interaction as approaches to abrogate 
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autoimmune diabetes. Despite focus on a particular signaling 
pathway, the Fas/FasL interaction, in a particular autoimmune 
disorder, T1D, the debate is rather relevant to multiple receptor/
ligand interactions of the TNF superfamily and to the entire range 
of inflammatory and autoimmune disorders.
WHY FOCUS On THE Fas/FasL 
inTERACTiOn?
The Fas/FasL interaction attracts attention as the common 
executioner of apoptosis in the TNF superfamily endowed with 
distinct characteristics (10). Like perforin/granzyme (11, 12), 
apoptotic signaling by Fas/FasL is localized by the requirement 
of direct contact between the effector and target cells, a unique 
feature caused by essential Fas receptor trimerization through 
engagement of the membrane-bound or oligomers of the ligand. 
The physiological significance of this receptor/ligand interaction 
is emphasized by lymphoproliferative disorders resulting from 
disruption of homeostatic negative regulation in Fas-deficient 
(lpr) and FasL-defective (gld) mice (13). Despite these particular 
characteristics of the Fas/FasL interaction, common physiologi-
cal trophic and apoptotic activities are shared by soluble ligands 
of the TNF superfamily, including TNFα and TNF-related 
apoptosis-inducing ligand receptor-1 (8).
pHYSiOLOGiCAL ACTiViTiES OF THE Fas/
FasL inTERACTiOn in pAnCREATiC 
iSLETS
non-immunogenic Activities
Several components of the signaling pathways associated with the 
Fas receptor are involved in insulin secretion (14, 15) and physi-
ological adjustment of β-cell mass. For example, the antiapoptotic 
factor FADD-like interleukin-1β-converting enzyme-inhibitory 
protein acting as a competitive caspase-8 antagonist promotes 
β-cell growth (16) under the inductive influence of interleukin-1β 
(IL-1β) (17). The Fas signaling pathway is also involved in regula-
tion of insulin secretion (14, 15).
immunogenic Activities
Physiological immune privilege uses FasL to defend organs from 
excessive inflammation that is often more harmful than pathogens, 
such as the anterior eye chamber and reproductive organs (10, 18). 
The pancreas is not one of the first line immune privileged tissues. 
However, both islet cells and vascular endothelium constitutively 
express FasL, while the Fas receptor is prevalently detected in 
resident macrophages (19, 20) and in inflamed islets (21, 22). 
The histological pattern of expression is suggestive of a defensive 
rim of FasL-expressing α- and β-cells in the islets of Langerhans 
(23). In fact, the frontier battleground between reactive T cells 
and tissues is islet vasculature (24), which constitutively expresses 
both Fas and FasL (25) and is therefore inherently insensitive to 
Fas-mediated apoptosis (26, 27). Protection of the islets by rela-
tive immune privilege represents a wider network of defense of 
the pancreas from incidental inflammation and immune attack 
(28) due to the extensive digestive capacity of pancreatic enzymes 
responsible for intestinal degradation of substrates, which might 
cause autolytic pancreatitis associated with severe morbidity and 
mortality.
THE Fas/FasL inTERACTiOn in 
inFLAMMATORY inSULiTiS
The Fas/FasL interaction As a Mechanism 
of β-Cell Death
Naïve islets express low levels of Fas (21, 22) and are intrinsi-
cally resistant to apoptosis triggered by this receptor (29, 30). 
Islets become gradually sensitive to apoptosis along the course 
of inflammation (31–33) due to increased Fas expression in 
β-cells (34, 35) and concomitant sensitization to Fas-mediated 
apoptosis (36, 37). Upregulated expression of the Fas recep-
tor is one of the many features of the transcriptional profiles 
of inflamed islets (38, 39) caused by activation of the nuclear 
factor-κB (NFκB) pathways (40). Induced Fas transcription 
and modulation of expression is caused by a number of pro-
inflammatory cytokines including IL-1α, IL-1β, IFNγ, nitric 
oxide (NO), and TNF-α that synergize with Fas as effector 
mechanisms of β-cell destruction (37, 41). Furthermore, 
both Fas expression induced by IL-1β (42) independent of 
NFκB activation (43, 44) and islet sensitization to apoptosis 
(45, 46) also evolve as direct consequences of hyperglycemia. 
The vast changes in transcriptomes and expression profiles of 
the inflamed islets may be viewed as an effort of the tissue to 
sustain insulin production and increase β-cell mass. However, 
cytokines secreted by the islets themselves paradoxally enhance 
immune activation and islet injury under inflammatory 
conditions (47–49).
potential Therapeutic Efficacy of Fas and/
or FasL neutralization
There is extensive evidence emphasizing a pivotal role of the 
Fas/FasL interaction in destructive insulitis in T1D, including 
experiments performed in transgenes deficient in the receptor 
and/or the ligand. For example, homozygous transgenes of 
non-obese diabetic (NOD) mice deficient in the Fas receptor 
(lpr) are protected from spontaneous evolution of diabetes, 
and heterozygous NOD.lpr transgenes display severe mono-
nuclear infiltration in the islets without hyperglycemia (50, 
51). However, NOD.lpr with and without superposed SCID 
mutations that display reduced incidence of spontaneous 
diabetes are susceptible to islet injury inflicted by adoptive 
transfer of diabetogenic cells (52). Likewise, disease incidence 
is reduced in FasL-deficient transgenes (gld) crossed onto 
the NOD background (52, 53). It is logical and tempting to 
approach inflammatory insulitis by neutralization of the Fas/
FasL interaction as one of the pivotal cytotoxic mechanisms 
used by diabetogenic effectors to attack β-cells (54–57), similar 
to the potential therapeutic benefit of TNF-α neutralization 
(58). However, it should be noted that FasL neutralization in 
the early postnatal period (53, 59) and in very early stages of 
inflammation slowed the pace but failed to prevent evolution 
of insulitis (60).
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ARGUMEnTS AGAinST THERApEUTiC 
nEUTRALiZATiOn OF THE Fas/FasL 
inTERACTiOn
Multiple immune Mechanisms Modulate 
inflammatory insulitis in the Absence of 
Functional Fas/FasL Signaling
The insights into effective disease diversion by interruption of 
functional Fas/FasL signaling led to identification of a number 
of indirect immunogenic factors that modulate the course of 
inflammation in transgenic mice. The variable patterns of disease 
expression in lpr transgenes are explained by two mechanisms 
beyond relative insensitivity of Fas-deficient islets to apoptosis. 
First, slow pace of spontaneous inflammatory insulitis is attrib-
uted to reduced aggressiveness and slow proliferation of effector 
lymphocytes of the lpr transgenes (61). Second, T  cells of lpr 
transgenes overexpress FasL, which inhibits the activity of endog-
enous and adoptively transferred diabetogenic cells (62). In vari-
ance, the pace of disease is slowed in gld transgenes by the activity 
of B lymphocytes that attenuate the course of inflammation by 
enhanced secretion of IL-10 (63). It is therefore evident that 
disruption of a pivotal immune homeostatic mechanism such as 
the Fas/FasL interaction has quite significant consequences that 
affect autoimmunity beyond direct participation as a cytotoxic 
mechanism of islet injury.
Multiple Redundant Mechanisms of β-Cell 
Death Obviate Fas neutralization
The difficulty in designation of an exact role of Fas-mediated 
apoptosis stands in the multiple, redundant, and interrelated 
mechanisms of β-cell death in T1D. The progressive involvement 
of Fas as a mediator of apoptosis along the course of inflamma-
tion has been challenged by a series of studies showing that this 
mechanism is neither obligatory nor essential in the process 
of destructive insulitis (64–68). Although Fas expression cor-
relates with β-cell inflammation and unequivocally contributes 
to destructive insulitis, a causal relationship is rather complex 
because apoptosis also correlates with upregulation of granzyme 
and TNF-R1 (69–72). In addition to the canonical mechanisms 
of apoptosis, islet injury is inflicted by a number of cytotoxic 
cytokines such as IL-1β, IFNγ, and NO (73, 74). It is quite difficult 
to attribute distinct activities to these interrelated mechanisms in 
the process of inflammatory insulitis, because most cytokines as 
well as TNFα induce Fas expression (21, 22, 29, 75).
individual Cytotoxic Mechanisms Are 
Dispensable in islet Destruction
Each one of the canonical cytotoxic mechanisms, including Fas, 
TNF-R1, and perforin/granzyme, is dispensable in autoimmune 
β-cell destruction (68, 75–80), as well as islet allograft rejection 
(27, 81). Outstanding is the compensation of dysfunctional Fas/
FasL interactions by other effector mechanisms of β-cell death 
(11, 35, 69, 82–84). Likewise, redundant activity of TGF-β, IL-1β, 
IFNγ, and NO is a common characteristic, as each individual 
cytotoxic mechanism is largely dispensable in β-cell lysis (36, 41, 
47, 85).
Harnessing physiological Mechanisms to 
Counteract islet inflammation
Extending the mechanism of immune privilege, negative regula-
tion of immune cells by TNF family receptor/ligand interactions 
has significant homeostatic impact on the intensity of inflam-
matory reactions. The common mechanism of tissue defense 
involves induction of apoptosis in autoreactive effectors sensitive 
to AICD at the level of pancreatic islets in situ (30, 62, 86). Physical 
elimination of diabetogenic cells has been attained by targeted 
expression of TNFα (87–90) and TGFβ (91, 92) under control of 
the insulin promoter, systemic administration of TNF-α (93–95), 
and overexpression of FasL protein in regulatory T cells (30, 96).
Therapeutic implications of the Fas/FasL 
interaction
The analysis presented here suggests that inhibition of the Fas/
FasL interaction has little potential efficacy in prevention of 
β-cell destruction by inflammatory insulitis, while targeted 
reinforcement of this mechanisms of immune homeostasis 
holds the potential to abrogate diabetic autoimmunity. Signaling 
through Fas receptor is one of many redundant and dispensable 
mechanisms of β-cell lysis by autoimmune attack; thus, neutrali-
zation provides transient symptomatic relief with little impact on 
alternative cytotoxic mechanisms (64–67). Implementation of 
FasL neutralization for treatment of T1D might even result in 
increased incidence of malignancies as seen with TNF-α inhibi-
tors (97–99). On the contrary, the role of FasL along TNF-α and 
perforin/granzyme is much more significant and non-redundant 
in immune homeostasis than in induction of β-cell death (10, 61, 
62, 88, 100). These homeostatic immune mechanisms counteract 
inflammation as mediators of effector cell death (27, 30, 86, 
89–96) are mandatory to reinstitution of suppressor mechanisms 
(101) and are indispensable in termination of inflammatory 
reactions (4).
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